RhumbLine Advisers’s Allena Pharmaceuticals ALNA Stock Holding History

RhumbLine Advisers’s Portfolio ALNA Stock Details ALNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-14,059	Closed	-$99K	–	3032
2019 Q1	$99K	Sell	14,059 -290	-2%	-$2.1K	﹤0.01%	2860
2018 Q4	$78K	Buy	+14,349	New	+$124K	﹤0.01%	2906
2018 Q3	–	Sell	-10,222	Closed	-$133K	–	2941
2018 Q2	$133K	Buy	+10,222	New	+$147K	﹤0.01%	2840

Other funds holding ALNA

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

DVC

Deer VII & Co Larchmont, New York $317M AUM 30.89% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RhumbLine Advisers's ALNA Position: Q2 2019 in Review

RhumbLine Advisers sold out of Allena Pharmaceuticals (ALNA) in Q2 2019, closing a stake of 14,059 shares — an estimated $99K sold.

RhumbLine Advisers first reported a position in ALNA in Q2 2018 and held it in 3 quarters. The position peaked at $133K in Q2 2018. 46 funds tracked by Wall St. Rank hold ALNA as of Q2 2019.

RhumbLine Advisers reported no remaining Allena Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
RhumbLine Advisers sold 14,059 Allena Pharmaceuticals shares in Q2 2019, an estimated $99K.
RhumbLine Advisers first reported a position in Allena Pharmaceuticals in Q2 2018 and held it in 3 quarters.
RhumbLine Advisers's Allena Pharmaceuticals position peaked at $133K in Q2 2018.
46 funds tracked by Wall St. Rank held Allena Pharmaceuticals as of Q2 2019.

Based on RhumbLine Advisers's 13F filing for Q2 2019, filed 14 Aug 2019.